Bassetti D, Cruciani M
Institute of Infectious Diseases, University of Verona, Italy.
Scand J Infect Dis Suppl. 1990;72:35-7.
Teicoplanin has been investigated mainly in adults and to a lesser extent in children. Pharmacological studies in children aged 2-12 years showed that a daily dose of 3-6 mg/kg of teicoplanin was insufficient to maintain microbiologically effective trough serum levels, while a regimen of 10 mg/kg/day was sufficient to obtain effective serum concentrations. Teicoplanin has been administered, alone or in combination therapy, to neutropenic or non-neutropenic paediatric patients. Combinations of teicoplanin (10 mg/kg/day) plus beta-lactams or aminoglycosides have been found effective in the treatment of febrile episodes in neutropenic (less than 500 pmn/microliters) children. Teicoplanin, 3-10 mg/kg i.v., has been administered as the sole antibiotic agent as a daily dose to more than 100 children and newborns with documented or suspected Gram-positive infections. Overall, teicoplanin was found to be a very effective and well tolerated treatment for Gram-positive infections in pediatric patients. Further trials are required to confirm these observations.
替考拉宁主要在成人中进行了研究，在儿童中的研究较少。对2至12岁儿童的药理学研究表明，每日剂量3至6毫克/千克的替考拉宁不足以维持微生物学上有效的谷浓度，而10毫克/千克/天的给药方案足以获得有效的血清浓度。替考拉宁已单独或联合用于中性粒细胞减少或非中性粒细胞减少的儿科患者。已发现替考拉宁（10毫克/千克/天）加β-内酰胺类或氨基糖苷类联合用药对治疗中性粒细胞减少（低于500个中性粒细胞/微升）儿童的发热性疾病有效。静脉注射3至10毫克/千克的替考拉宁作为每日剂量已单独用于100多名有记录或疑似革兰氏阳性感染的儿童和新生儿。总体而言，替考拉宁被发现是治疗儿科患者革兰氏阳性感染的一种非常有效且耐受性良好的药物。需要进一步的试验来证实这些观察结果。
